Replication-detective genomic HSV gene therapy vectors: Design, production and CNS applications

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 4, 2005, Pages 326-336

  Burton, Edward A ^a   Fink, David J ^b   Glorioso, Joseph C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Gene therapy; Herpes simplex virus; Latency promoter; Malignant glioma; Vector manufacture; Vector targeting

Indexed keywords

DOUBLE STRANDED DNA; GANCICLOVIR; GAP JUNCTION PROTEIN; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

DNA VIRUS; DRUG DESIGN; DRUG TARGETING; GAMMA KNIFE RADIOSURGERY; GENE DELETION; GENE EXPRESSION; GLIOBLASTOMA; HERPES; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS VECTOR; NERVE CELL; NERVE DEGENERATION; NONHUMAN; NUREL C2 VECTOR; REVIEW; SUICIDE GENE THERAPY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; GLIOMA; HUMAN; METHODOLOGY; REPORTER GENE;

DNA VIRUSES; SIMPLEXVIRUS;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; GENOME, VIRAL; GLIOMA; HUMANS; SIMPLEXVIRUS; TRANSFECTION; TRANSGENES; VIRUS REPLICATION;

EID: 23344452079     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Wade-Martins R, Saeki Y, Chiocca EA: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 7(5 Pt 1):604-612.
2. Wade-Martins R, White RE, Kimura H, Cook PR, James MR: Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene. Nat Biotechnol (2000) 18(12):1311-1314.
3. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y: An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 19(11):1067-1070.
4. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 5(12):1593-1603.
5. Ozuer A, Wechuck JB, Goins WF, Wolfe D, Glorioso JC, Ataai MM: Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng (2002) 77(6):685-692.
6. Hobbs WE 2nd, DeLuca NA: Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol (1999) 73(10):8245-8255.
7. Samaniego LA, Neiderhiser L, DeLuca NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol (1998) 72(4):3307-3320.
8. Chen X, Li J, Mata M, Goss J, Wolfe D, Glorioso JC, Fink DJ: Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol (2000) 74(21):10132-10141.
9. Niranjan A, Wolfe D, Tamura M, Soares MK, Krisky DM, Lunsford LD, Li S, Fellows-Mayle W, DeLuca NA, Cohen JB, Glorioso JC: Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther (2003) 8(4):530-542.
10. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D: Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 375(6530):411-415.
11. Fruh K, Ahn K, Diaballah H, Sempe P, van Endert PM, Tampe R, Peterson PA, Yang Y: A viral inhibitor of peptide transporters for antigen presentation. Nature (1995) 375(6530):415-418.
12. Todo T, Martuza RL, Rabkin SD, Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA (2001) 98(11):6396-6401.
13. Lilley CE, Groutsi F, Han Z, Palmer JA, Anderson PN, Latchman DS, Coffin RS: Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J Virol (2001) 75(9):4343-4356.
14. Palmer JA, Branston RH, Lilley CE, Robinson MJ, Groutsi F, Smith J, Latchman DS, Coffin RS: Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol (2000) 74(12):5604-5618.
15. Marshall KR, Lachmann RH, Efstathiou S, Rinaldi A, Preston CM: Long-term transgene expression in mice infected with a herpes simplex virus type 1 mutant severely impaired for immediate-early gene expression. J Virol (2000) 74(2):956-964.
16. Scarpini CG, May J, Lachmann RH, Preston CM, Dunnett SB, Torres EM, Efstathiou S: Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors. Gene Ther (2001) 8(14):1057-1071.
17. Bai Q, Burton EA, Goins WF, Glorioso JC: Modifying the tropism of HSV vectors for gene therapy applications. In: Vector Targeting for Therapeutic Gene Delivery. Douglas J, Curiel D (Eds), John Wiley & Sons, Hoboken, NJ, USA (2002).
18. Laquerre S, Anderson DB, Stolz DB, Glorioso JC: Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol (1998) 72(12):9683-9697.
19. Anderson DB, Laquerre S, Ghosh K, Ghosh HP, Goins WF, Cohen JB, Glorioso JC: Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol (2000) 74(5):2481-2487.
20. Nakano K, Asano R, Tsumoto K, Kwon H, Goins WF, Kumagai I, Cohen JB, Glorioso JC: Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther (2005) 11(4):617-26.
21. L flanking repeats. J Virol (1994) 68(4):2239-2252.
22. Puskovic V, Wolfe D, Goss J, Huang S, Mata M, Glorioso JC, Fink DJ: Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther (2004) 10(1):67-75.
23. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F: GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (1993) 260(5111):1130-1132.
24. Smith C, Lachmann RH, Efstathiou S: Expression from the herpes simplex virus type 1 latency-associated promoter in the murine central nervous system. J Gen Virol (2000) 3(3):649-662.
25. Ozuer A, Wechuck JB, Russell B, Wolfe D, Goins WF, Glorioso JC, Ataai MM: Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnol Prog (2002) 18(3):476-482.
26. Jiang C, Wechuck JB, Goins WF, Krisky DM, Wolfe D, Ataai MM, Glorioso JC: Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol (2004) 78(17):8994-9006.
27. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R et al: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 7(10):859-866.
28. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther (2000) 7(10):867-874.
29. Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, Yoshimine T, Cohen JB, Glorioso JC: HSV vector cytotoxicity is inversely correlated with effective tk/GCV suicide gene therapy of rat gliosarcoma. Gene Ther (2000) 7(17):1483-1490.
30. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC: Connexin 43-enhanced suicide gene therapy using herpes viral vectors. Mol Ther (2000) 1(1):71-81.
31. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB, Glorioso JC: Effective treatment of experimental glioblastoma by HSV vector-mediated TNFα and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther (2000) 2(2):114-120.
32. Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, Kondziolka D, Krisky D, Goss J, DeLuca N, Murphey-Corb M, Glorioso JC: Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther (2004) 11(23):1675-1684.